Market Overview:
The global nasal spray market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, growing awareness about the benefits of using nasal sprays, and technological advancements in nasal spray devices. The global nasal spray market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into corticosteroids, bronchodilators, combinations, decongestant sprays, and others. The corticosteroid segment is expected to dominate the global nasal spray market during the forecast period owing to its high efficacy in treating respiratory diseases such as asthma and COPD.
Product Definition:
A nasal spray is a device that dispenses medication into the nose in a fine mist. It is used to relieve congestion, allergies, and colds.
Corticosteroids:
Corticosteroids are naturally occurring hormones that are found in the adrenal glands. Corticosteroid drugs include a variety of topical creams, gels, ointments, solutions and sprays used to reduce inflammation or redness caused by skin conditions like eczema or psoriasis. Corticosteroids can also be administered through injections into the vein ( intravenous corticosteroid drug delivery system) or they can be taken by mouth as tablets or capsules.
Bronchodilators:
Bronchodilators are drugs that widen the airways and increase the flow of air in to lungs. They work by relaxing smooth muscles in the bronchi of lungs, which reduces resistance to airflow. This allows more oxygen to get into blood cells and helps fight respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and other lung disorders.
Application Insights:
The other application segment includes the treatment of snoring, nasal congestion and sinusitis. The COPD segment held the largest market share in 2017 owing to a rise in prevalence of chronic bronchitis and emphysema. According to estimates reported by the CDC, around 30 million adults have COPD which is expected to increase with aging as well as due to smoking tobacco. Thus, increasing incidence of COPD is expected fuel demand for nasal sprays in near future.
On the other hand, asthma held a significant market share in 2017 owing to high incidence coupled with prevalence of this disease across all age groups and both genders globally. According an article published by Global Asthma Report Card 2018 states that around 463 million people were affected by asthma worldwide which was an increase from 2016 when 420 million people were registered globally having this condition (asthma).
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players and increased adoption of advanced products for treatment options are some factors driving the regional market. In addition, high healthcare expenditure and favorable reimbursement policies are also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness significant growth over the forecast period owing to rising disposable income, increasing population base with various health conditions, improving healthcare infrastructure along with growing awareness about nasal sprays among patients is expected to drive demand for nasal spray drugs in this region over next eight years.
Growth Factors:
- Increasing incidence of respiratory diseases: The global nasal spray market is expected to grow at a CAGR of 5.5% during the forecast period owing to the increasing incidence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia.
- Technological advancements: The development of novel technologies for nasal sprays is expected to drive the growth of this market during the forecast period. For instance, in 2017, GlaxoSmithKline plc (GSK) launched its Ellipta dry powder inhaler that can be used with its Advair Diskus and Serevent Diskus products for the treatment of asthma and COPD. This product offers a new option for patients who are looking for an alternative to metered-dose inhalers (MDIs).
- Rising awareness about preventive measures: There has been an increase in awareness among people about preventive measures against respiratory diseases such as asthma and COPD, which is driving demand for nasal sprays globally. In addition, governments are also promoting awareness programs about these diseases through various campaigns and initiatives, thereby propelling growth prospects for this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Nasal Spray Market Research Report
By Type
Corticosteroids, Bronchodilators, Combinations, Decongestant Sprays, Others
By Application
Asthma, COPD, Allergic Rhinitis, Other
By Companies
Teva, Sandoz (Novartis AG), Mylan, Allergan PLC, Cipla, Akorn, Apotex, Sun Pharma (Ranbaxy), Nephron Pharma, Beximco Pharma, Hikma (Roxane), XIANJU PHARMA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Nasal Spray Market Report Segments:
The global Nasal Spray market is segmented on the basis of:
Types
Corticosteroids, Bronchodilators, Combinations, Decongestant Sprays, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Asthma, COPD, Allergic Rhinitis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Sandoz (Novartis AG)
- Mylan
- Allergan PLC
- Cipla
- Akorn
- Apotex
- Sun Pharma (Ranbaxy)
- Nephron Pharma
- Beximco Pharma
- Hikma (Roxane)
- XIANJU PHARMA
Highlights of The Nasal Spray Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- Bronchodilators
- Combinations
- Decongestant Sprays
- Others
- By Application:
- Asthma
- COPD
- Allergic Rhinitis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nasal Spray Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nasal spray is a medication that is used to treat allergies, colds, and other respiratory infections. It comes in a variety of forms, including inhalers and nasal sprays. Nasal spray is usually effective when taken as soon as symptoms start.
Some of the major players in the nasal spray market are Teva, Sandoz (Novartis AG), Mylan, Allergan PLC, Cipla, Akorn, Apotex, Sun Pharma (Ranbaxy), Nephron Pharma, Beximco Pharma, Hikma (Roxane), XIANJU PHARMA.
The nasal spray market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nasal Spray Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nasal Spray Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nasal Spray Market - Supply Chain
4.5. Global Nasal Spray Market Forecast
4.5.1. Nasal Spray Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nasal Spray Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nasal Spray Market Absolute $ Opportunity
5. Global Nasal Spray Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nasal Spray Market Size and Volume Forecast by Type
5.3.1. Corticosteroids
5.3.2. Bronchodilators
5.3.3. Combinations
5.3.4. Decongestant Sprays
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nasal Spray Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nasal Spray Market Size and Volume Forecast by Application
6.3.1. Asthma
6.3.2. COPD
6.3.3. Allergic Rhinitis
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nasal Spray Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nasal Spray Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nasal Spray Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nasal Spray Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nasal Spray Demand Share Forecast, 2019-2029
9. North America Nasal Spray Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nasal Spray Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nasal Spray Market Size and Volume Forecast by Application
9.4.1. Asthma
9.4.2. COPD
9.4.3. Allergic Rhinitis
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nasal Spray Market Size and Volume Forecast by Type
9.7.1. Corticosteroids
9.7.2. Bronchodilators
9.7.3. Combinations
9.7.4. Decongestant Sprays
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nasal Spray Demand Share Forecast, 2019-2029
10. Latin America Nasal Spray Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nasal Spray Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nasal Spray Market Size and Volume Forecast by Application
10.4.1. Asthma
10.4.2. COPD
10.4.3. Allergic Rhinitis
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nasal Spray Market Size and Volume Forecast by Type
10.7.1. Corticosteroids
10.7.2. Bronchodilators
10.7.3. Combinations
10.7.4. Decongestant Sprays
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nasal Spray Demand Share Forecast, 2019-2029
11. Europe Nasal Spray Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nasal Spray Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nasal Spray Market Size and Volume Forecast by Application
11.4.1. Asthma
11.4.2. COPD
11.4.3. Allergic Rhinitis
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nasal Spray Market Size and Volume Forecast by Type
11.7.1. Corticosteroids
11.7.2. Bronchodilators
11.7.3. Combinations
11.7.4. Decongestant Sprays
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nasal Spray Demand Share, 2019-2029
12. Asia Pacific Nasal Spray Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nasal Spray Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nasal Spray Market Size and Volume Forecast by Application
12.4.1. Asthma
12.4.2. COPD
12.4.3. Allergic Rhinitis
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nasal Spray Market Size and Volume Forecast by Type
12.7.1. Corticosteroids
12.7.2. Bronchodilators
12.7.3. Combinations
12.7.4. Decongestant Sprays
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nasal Spray Demand Share, 2019-2029
13. Middle East & Africa Nasal Spray Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nasal Spray Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nasal Spray Market Size and Volume Forecast by Application
13.4.1. Asthma
13.4.2. COPD
13.4.3. Allergic Rhinitis
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nasal Spray Market Size and Volume Forecast by Type
13.7.1. Corticosteroids
13.7.2. Bronchodilators
13.7.3. Combinations
13.7.4. Decongestant Sprays
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nasal Spray Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Nasal Spray Market: Market Share Analysis
14.2. Nasal Spray Distributors and Customers
14.3. Nasal Spray Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sandoz (Novartis AG)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Allergan PLC
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cipla
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Akorn
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Apotex
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sun Pharma (Ranbaxy)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Nephron Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Beximco Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hikma (Roxane)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. XIANJU PHARMA
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
